A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

NCT07215559 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity
Overweight
Diabetes Mellitus, Type 2

Interventions

DRUG: Macupatide
DRUG: Eloralintide
DRUG: Macupatide Placebo
DRUG: Eloralintide Placebo

Sponsor

Eli Lilly and Company